Neurology · AntiepilepticRegulatory Approvalregulatorymid-term

FDA Approves Supplement for Levetiracetam by Chartwell RX

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen35 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/6/2026, 12:01:41 PM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of a supplemental application for levetiracetam by Chartwell RX is significant as it may strengthen their market position in the antiepileptic sector. This development necessitates close monitoring of competitive responses and market dynamics, particularly for other manufacturers of similar products. Regulatory context from FDA (FDA AP — LEVETIRACETAM (SUPPL)) supports the near-term read. Assessment grounded in 17 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and pricing strategies for levetiracetam alternatives. The strongest clinical anchor is A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 t (ClinicalTrials.gov), sponsor/company relevance (merck). In Neurology · Antiepileptic, 8 regulatory and 0 competitive items passed relevance filtering for Chartwell RX.

Competitive Pressure

The most relevant competitive pressure comes from This approval may enhance Chartwell RX's position in the antiepileptic market, potentially impacting competitors with similar products..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEVETIRACETAM (SUPPL) (FDA). Entity match (chartwell rx). This approval indicates a successful regulatory pathway for Chartwell RX, which may influence future submissions and compliance strategies for other companies in the sector.

Key Risks

Elevated medium regulatory exposure for Chartwell RX could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for Chartwell RX, potentially affecting pricing strategies and revenue for competitors in the antiepileptic market.
Upside for Chartwell RX may improve if Post-activation performance enhancement (PAPE) and taurine combination improves anaerobic performance in highly trained wrestlers: a double-blind, randomized, crossover study. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the implications of this approval on market share and pricing strategies for levetiracetam alternatives.

What Would Change This Assessment

This becomes more urgent if Monitor for market entry timelines and any competitive responses from other antiepileptic drug manufacturers.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEVETIRACETAM (SUPPL)
FDAhigh relevance
Entity match (chartwell rx)
FDA document
View source
FDA AP — LEVETIRACETAM (SUPPL)
FDAhigh relevance
Entity match (levetiracetam)
FDA document
View source
FDA AP — LEVETIRACETAM IN SODIUM CHLORIDE (ORIG)
FDAhigh relevance
Entity match (levetiracetam)
FDA document
View source
FDA AP — LEVETIRACETAM (SUPPL)
FDAhigh relevance
Entity match (levetiracetam)
Raw openFDA evidence
View raw openFDA evidence
FDA AP — LEVETIRACETAM (SUPPL)
FDAhigh relevance
Entity match (chartwell rx)
Raw openFDA evidence
View raw openFDA evidence
FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 t
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
GYNEMESH PS Mesh Post Marketing Clinical Follow-Up Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
AIM-IBD: A Phase 2b Trial of Microbiome-Targeted Investigational Product in Ulcerative Colitis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

No evidence in this category.

Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Post-activation performance enhancement (PAPE) and taurine combination improves anaerobic performance in highly trained wrestlers: a double-blind, randomized, crossover study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Chartwell RX
levetiracetam
antiepileptic market
competitors

Commercial impact

medium

The approval could lead to increased market share for Chartwell RX, potentially affecting pricing strategies and revenue for competitors in the antiepileptic market.

Regulatory impact